Role of natriuretic peptides in cardiovascular surgery

References

• Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam. Clin. Pharmacol.19, 411–419 (2005).
   PubMed Web of Science ®Google Scholar
• Rose RA, Lomax AE, Giles WR. Inhibition of L-type Ca2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect. Am. J. Physiol. Heart Circ. Physiol.285(6), H2454–H2462 (2003).
   PubMed Web of Science ®Google Scholar
• Huxley VH, Tucker VL, Verburg KM, Freeman RH. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ. Res.60, 304–307 (1987).
   PubMed Web of Science ®Google Scholar
• McKay MK, Huxley VH. ANP increases capillary permeability to protein independent of perfusate protein composition. Am. J. Physiol.268, H1139–H1148 (1995).
   PubMedGoogle Scholar
• Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human natriuretic peptide on human artery and vein tissue. Am. J. Hypertens.9, 432–436 (1996).
   PubMed Web of Science ®Google Scholar
• Lanese DM, Yuan BH, Falk SA, Conger JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am. J. Physiol.261, F1102–F1109 (1991).
   PubMed Web of Science ®Google Scholar
• Huang CL, Lewicki J, Johnson LK, Cogan MG. Renal mechanism of action of rat atrial natriuretic factor. J. Clin. Invest.75, 769–773 (1985).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation111, 1487–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA293, 1900–1905 (2005).
   PubMed Web of Science ®Google Scholar
• Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA296, 1465–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP et al.; Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med.343, 246–253 (2000).
   PubMed Web of Science ®Google Scholar
• Burger AJ, Horton DP, LeJemtel T et al. Prospective randomized evaluation of cardiac ectopy with dobutamine or natrecor therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J.144, 1102–1108 (2002).
   PubMed Web of Science ®Google Scholar
• Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am. J. Emerg. Med.23, 327–331 (2005).
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA287, 1531–1540 (2002).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Saltzberg MT, Berkowitz RL et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am. J. Cardiol.94, 595–601 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation84, 1581–1588 (1991).
   PubMed Web of Science ®Google Scholar
• Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J. Card. Fail.2, S277–S285 (1996).
   PubMedGoogle Scholar
• Lainchbury JG, Richards AM, Nicholls MG et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension30, 398–404 (1997).
   PubMed Web of Science ®Google Scholar
• Marcus LS, Hart D, Packer M, Yushak M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation94, 3184–3189 (1996).
   PubMed Web of Science ®Google Scholar
• Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest. Heart Fail.11, 30–38 (2005).
   PubMedGoogle Scholar
• Hayashi Y, Ohtani M, Hiraishi T, Kobayashi Y. Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide. J. Thorac. Cardiovasc. Surg.124, 206–209 (2002).
   PubMed Web of Science ®Google Scholar
• Beaver TM, Winterstein A, Hess PJ Jr et al. Nesiritide following maze and mitral valve surgery. J. Card. Surg.23, 431–436 (2008).
   PubMed Web of Science ®Google Scholar
• Rahman SN, Kim GE, Mathew AS et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int.45, 1731–1738 (1994).
   PubMed Web of Science ®Google Scholar
• Allgren RL, Marbury TC, Rahman SN et al.; Auriculin Anaritide Acute Renal Failure Study Group. Anaritide in acute tubular necrosis. N. Engl. J. Med.336, 828–834 (1997).
   PubMed Web of Science ®Google Scholar
• Lewis J, Salem MM, Chertow GM et al.; Anaritide Acute Renal Failure Study Group. Atrial natriuretic factor in oliguric acute renal failure. Am. J. Kidney Dis.36, 767–774 (2000).
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol.4(2), 261–272 (2009).
   PubMed Web of Science ®Google Scholar
• Valsson F, Ricksten SE, Hedner T, Lundin S. Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Int. Care Med.22, 230–236 (1996).
   PubMed Web of Science ®Google Scholar
• Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit. Care Med.32(6), 1310–1315 (2004).
   PubMed Web of Science ®Google Scholar
• Beaver TM, Winterstein AG, Shuster JJ et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin. Cardiol.29, 18–24 (2006).
   PubMed Web of Science ®Google Scholar
• Mentzer RM Jr, Oz MC, Sladen RN et al.; NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J. Am. Coll. Cardiol.49, 716–726 (2007).
   PubMed Web of Science ®Google Scholar
• Ejaz AA, Martin TD, Johnson RJ et al. Prophylactic nesiritide does not prevent dialysis or all cause mortality in high-risk cardiac surgery patients. J. Vasc. Cardiothorac. Surg. (2009) (In Press).
   Google Scholar
• Ejaz AA, Heinig ME, Kazory A, Bihorac A, Hobson CE, Beaver TM. The rise and fall of natriuretic peptides in acute kidney injury: a misunderstood relationship? Rev. Cardiovasc. Med.8(Suppl. 5), S32–S37 (2007).
   PubMed Web of Science ®Google Scholar
• Devarajan P. Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol.17, 1503–1520 (2006).
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care11(2), R31 (2007).
   PubMed Web of Science ®Google Scholar
• Ponte B, Felipe C, Muriel A, Tenorio MT, Liaño F. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol. Dial. Transplant.23, 3859–3866 (2008).
   PubMed Web of Science ®Google Scholar
• Chen HH, Sundt TM, Cook DJ. Heublein DM, Burnett JC Jr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation116, I134–138 (2007).
   PubMed Web of Science ®Google Scholar
• Dyke CM, Bhatia D, Aronson S, Moazami N, Mentzer RM Jr. Perioperative nesiritide and possible renal protection in patients with moderate to severe kidney dysfunction. J. Thorac. Cardiovasc. Surg.136, 1369–1370 (2008).
   PubMed Web of Science ®Google Scholar
• Yavas S, Segal MS, Sungur M, Gabrielli A, Layon AJ, Bihorac A. Postoperative acute kidney injury is an important determinant of long term survival of surgical patients. Blood Purif.25, 183–208 (2007).
   Google Scholar
• Leacche M, Rawn JD, Mihaljevic T et al. Outcomes in patients with normal serum creatinine and with artificial renal support for acute renal failure developing after coronary artery bypass grafting. Am. J. Cardiol.93, 353–356 (2004).
   PubMed Web of Science ®Google Scholar
• Loef BG, Epema AH, Smilde TD et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J. Am. Soc. Nephrol.16, 195–200 (2005).
   PubMed Web of Science ®Google Scholar
• Oeyen S, Vandijck D, Benoit D, Decruyenaere J, Annemans L, Hoste E. Long-term outcome after acute kidney injury in critically-ill patients. Acta Clin. Belg.2, 337–340 (2007).
   Google Scholar
• Thakar CV, Worley S, Arrigain S, Yared JP, Paganini EP. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int.67, 1112–1119 (2005).
   PubMed Web of Science ®Google Scholar